Radiotherapy and CDK inhibitors: Opportunities and risks

Area of Science:

• Oncology
• Radiotherapy
• Pharmacology

Background:

• CDK4/6 inhibitors are standard treatment for metastatic HR+/HER2- breast cancer.
• Combining CDK4/6 inhibitors with radiotherapy is being investigated for enhanced anti-cancer effects.
• Pre-clinical data suggest potential synergistic outcomes in various cancer types.

Purpose of the Study:

• To review the benefits and risks of combining CDK4/6 inhibitors with radiotherapy.
• To synthesize current evidence on the safety and efficacy of this combined treatment modality.

Main Methods:

• Literature review of pre-clinical and clinical studies.
• Analysis of reported synergistic effects and toxicities.
• Identification of ongoing prospective clinical trials.

Main Results:

• Pre-clinical studies indicate a potential synergistic effect between CDK4/6 inhibitors and radiotherapy.
• Retrospective clinical studies suggest increased acute toxicity, particularly with digestive or pulmonary irradiation.
• Discontinuation of CDK4/6 inhibitors prior to radiotherapy is suggested based on toxicity findings.

Conclusions:

• The combination of CDK4/6 inhibitors and radiotherapy presents a complex risk-benefit profile.
• Careful patient selection and treatment sequencing may be necessary to mitigate toxicity.
• Prospective clinical trials are crucial to establish the definitive safety and efficacy of this combination therapy.